Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2012. The report details a specific share repurchase transaction executed on February 8, 2012, in accordance with shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure and share repurchase activity.
- Shares Purchased: 575,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,401.0 pence per share; lowest price paid was 1,382.5 pence per share.
- Treasury Holdings (Settled): 501,157,927 shares (9.02% of total issued share capital).
- Treasury Holdings (Including Unsettled): 501,732,927 shares (9.93% of total voting rights).
- Shares in Issue (Excluding Treasury): 5,051,841,017 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 575,000 shares on February 8, 2012. Consequently, the percentage of total voting rights held in Treasury increased to 9.93% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a routine disclosure of a share buyback transaction and does not constitute an offer to purchase or subscribe for securities.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (501,157,927 settled) against the company's latest annual report.
- Confirm the total issued share capital excluding Treasury shares (5,051,841,017) for voting rights calculations.
- Review the price range paid (1,382.5 to 1,401.0 pence) to assess the cost of capital return relative to market prices on February 8, 2012.
- Note that this filing does not contain operational or financial performance data for the period.